JP2013027404A5 - - Google Patents

Download PDF

Info

Publication number
JP2013027404A5
JP2013027404A5 JP2012235325A JP2012235325A JP2013027404A5 JP 2013027404 A5 JP2013027404 A5 JP 2013027404A5 JP 2012235325 A JP2012235325 A JP 2012235325A JP 2012235325 A JP2012235325 A JP 2012235325A JP 2013027404 A5 JP2013027404 A5 JP 2013027404A5
Authority
JP
Japan
Prior art keywords
seq
factor
amino acid
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012235325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013027404A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013027404A publication Critical patent/JP2013027404A/ja
Publication of JP2013027404A5 publication Critical patent/JP2013027404A5/ja
Pending legal-status Critical Current

Links

JP2012235325A 2006-11-02 2012-10-25 ヒト化抗d因子抗体 Pending JP2013027404A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85650506P 2006-11-02 2006-11-02
US60/856,505 2006-11-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009535444A Division JP2010508819A (ja) 2006-11-02 2007-10-31 ヒト化抗d因子抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014049395A Division JP5918794B2 (ja) 2006-11-02 2014-03-12 ヒト化抗d因子抗体

Publications (2)

Publication Number Publication Date
JP2013027404A JP2013027404A (ja) 2013-02-07
JP2013027404A5 true JP2013027404A5 (https=) 2014-05-01

Family

ID=39345075

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2009535444A Withdrawn JP2010508819A (ja) 2006-11-02 2007-10-31 ヒト化抗d因子抗体
JP2012235324A Expired - Fee Related JP5474158B2 (ja) 2006-11-02 2012-10-25 ヒト化抗d因子抗体
JP2012235325A Pending JP2013027404A (ja) 2006-11-02 2012-10-25 ヒト化抗d因子抗体
JP2014049395A Active JP5918794B2 (ja) 2006-11-02 2014-03-12 ヒト化抗d因子抗体
JP2015171685A Withdrawn JP2015214591A (ja) 2006-11-02 2015-09-01 ヒト化抗d因子抗体
JP2017157499A Pending JP2017200492A (ja) 2006-11-02 2017-08-17 ヒト化抗d因子抗体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009535444A Withdrawn JP2010508819A (ja) 2006-11-02 2007-10-31 ヒト化抗d因子抗体
JP2012235324A Expired - Fee Related JP5474158B2 (ja) 2006-11-02 2012-10-25 ヒト化抗d因子抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014049395A Active JP5918794B2 (ja) 2006-11-02 2014-03-12 ヒト化抗d因子抗体
JP2015171685A Withdrawn JP2015214591A (ja) 2006-11-02 2015-09-01 ヒト化抗d因子抗体
JP2017157499A Pending JP2017200492A (ja) 2006-11-02 2017-08-17 ヒト化抗d因子抗体

Country Status (35)

Country Link
US (10) US8067002B2 (https=)
EP (4) EP3466971A1 (https=)
JP (6) JP2010508819A (https=)
KR (6) KR20160092061A (https=)
CN (7) CN106188303A (https=)
AR (2) AR063760A1 (https=)
AU (1) AU2007313685C1 (https=)
BR (1) BRPI0716299A2 (https=)
CA (2) CA2939806A1 (https=)
CL (1) CL2007003161A1 (https=)
CO (1) CO6190543A2 (https=)
CR (1) CR10827A (https=)
DK (2) DK2097455T3 (https=)
EC (1) ECSP099379A (https=)
ES (2) ES2700609T3 (https=)
HK (2) HK1215712A1 (https=)
HR (1) HRP20181969T1 (https=)
IL (3) IL198512A (https=)
LT (1) LT2907827T (https=)
MA (1) MA30962B1 (https=)
MX (1) MX2009004665A (https=)
MY (2) MY183804A (https=)
NO (1) NO20092121L (https=)
NZ (3) NZ576812A (https=)
PE (2) PE20081259A1 (https=)
PH (1) PH12015501763A1 (https=)
PL (2) PL2097455T3 (https=)
PT (2) PT2907827T (https=)
RS (1) RS58233B1 (https=)
RU (3) RU2474589C9 (https=)
SI (2) SI2097455T1 (https=)
TW (5) TWI391401B (https=)
UA (2) UA101603C2 (https=)
WO (1) WO2008055206A2 (https=)
ZA (2) ZA200903088B (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261103B2 (en) * 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
CN106188303A (zh) 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
PE20100092A1 (es) * 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
BRPI0913366A8 (pt) * 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
NZ603698A (en) * 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
GB2476606B (en) 2008-09-08 2012-08-08 Virginia Tech Intell Prop Systems, devices, and methods for managing energy usage
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
KR20110020642A (ko) 2009-08-24 2011-03-03 삼성전자주식회사 사용자 접근을 인식하여 반응하는 gui제공 장치 및 방법
KR20120060877A (ko) * 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
IN2012DN02634A (https=) 2009-10-15 2015-09-04 Abbvie Inc
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
WO2011143637A1 (en) 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103517921B (zh) 2010-12-21 2017-07-18 Abbvie 公司 IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途
EP2661433B1 (en) 2011-01-04 2017-08-16 Novartis AG Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
JP6214647B2 (ja) 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
AU2013318047A1 (en) 2012-09-19 2015-03-12 Genentech, Inc. Methods and compositions for preventing norleucine misincorporation into proteins
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
AU2014306867B2 (en) * 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US20170137535A1 (en) * 2015-10-30 2017-05-18 Genentech, Inc. Anti-factor d antibody formulations
KR102162324B1 (ko) 2015-10-30 2020-10-07 제넨테크, 인크. 항-HtrA1 항체 및 이의 사용 방법
WO2017075252A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
HK1257425A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 测量因子d活性和因子d抑制剂效力的方法
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CA3024359A1 (en) 2016-06-23 2017-12-28 Jiangsu Hengrui Medicine Co., Ltd. Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
EP3580241A4 (en) 2017-02-10 2021-01-06 The Trustees Of The University Of Pennsylvania ANTIFACTOR D ANTIBODIES AND USES THEREOF
CN106905431B (zh) * 2017-04-10 2020-01-17 旭华(上海)生物研发中心有限公司 抗人补体d因子的单克隆抗体及其用途
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
FR3071483B1 (fr) * 2017-09-27 2020-11-27 Airbus Operations Sas Systeme de surveillance de braquage d'une roulette de train d'atterrissage d'un aeronef
WO2019109238A1 (en) * 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US11166910B2 (en) 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
CN110240652B (zh) * 2019-06-05 2022-09-06 百奥泰生物制药股份有限公司 抗补体d因子抗体及其应用
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7829595B2 (ja) * 2021-04-09 2026-03-13 武田薬品工業株式会社 補体因子dを標的とする抗体及びその使用
CN119176879B (zh) * 2024-09-05 2025-08-05 西安市中心血站(陕西省血液中心) 一种中和抗d抗体的抗独特型抗体及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
CA2018228C (en) 1989-06-05 1996-02-27 Nancy L. Parenteau Cell culture systems and media
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5897475A (en) 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
AU756490B2 (en) 1997-08-26 2003-01-16 Abgenix, Inc. A process for inhibiting complement activation via the alternative pathway
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2288649T3 (es) 1997-11-21 2008-01-16 Genentech, Inc. Antigenos tipo a-33 y sus utilizaciones farmacologicas.
EP1053245A4 (en) 1998-02-09 2002-04-17 Human Genome Sciences Inc 45 HUMAN SECRETED PROTEINS
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
BR9909220A (pt) 1998-02-20 2000-11-21 Tanox Inc Inibidores de ativação de complemento
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
AU5587799A (en) 1998-08-27 2000-03-21 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
KR100468978B1 (ko) 1998-12-16 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
JP3993746B2 (ja) 1998-12-22 2007-10-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ514091A (en) 1999-03-11 2004-01-30 Rmf Dictagene S Vascular adhesion molecules and modulation of their function
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
JP2003514541A (ja) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 18個のヒト分泌タンパク質
EP1672070A3 (en) 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001249410A1 (en) * 2000-03-23 2001-10-03 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation
AU2001261103B2 (en) 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
CA2416538A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001296594A1 (en) 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
MXPA03003144A (es) 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
BRPI0211953B8 (pt) 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
WO2004022594A2 (en) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CN102618644A (zh) 2004-11-18 2012-08-01 耶鲁大学 治疗眼病的方法和组合物
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP2357254A1 (en) 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
FI118793B (fi) * 2005-07-11 2008-03-31 Olli Friman Rullaluistimen pyörän vierintälaakerin suojalevy
MX351152B (es) 2005-10-08 2017-10-04 Potentia Pharmaceuticals Inc Compstatina y analogos de la misma para tratar trastornos oculares.
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US7941135B2 (en) 2006-03-22 2011-05-10 Alcatel-Lucent Usa Inc. Methods of performing live monitoring of a wireless communication network
CN106188303A (zh) * 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados

Similar Documents

Publication Publication Date Title
JP2013027404A5 (https=)
JP2014110810A5 (https=)
RU2019102393A (ru) Гуманизированные антитела к фактору d и их применения
US11685789B2 (en) CD47 antigen-binding molecules
JP7357038B2 (ja) 改善されたtnf結合因子
CN108473566B (zh) 抗N3pGlu淀粉样蛋白β肽抗体及其用途
US20240010733A1 (en) Antibodies that bind to c-type lectin domain family 2 member d (clec2d)
JP2018520139A (ja) エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法
JP2016524592A5 (https=)
Al Ustwani et al. Genetics on a WHIM
JP2018502060A5 (https=)
JP2017522903A5 (https=)
JP2011514150A5 (https=)
EP3161007A1 (en) Multispecific antibody constructs
JP2014526898A5 (https=)
RU2015143886A (ru) Антитела к тау и способы применения
JP2013542914A5 (https=)
JP2014518883A5 (https=)
JP2016525502A5 (https=)
JP2013506425A5 (https=)
JP2015502340A5 (https=)
EP3625265A1 (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
CN104507964A (zh) P2x7受体拮抗剂和激动剂
JP2019504822A5 (https=)
JP2017504321A5 (https=)